Novartis has revealed that Mayzent (siponimod) has been recommended by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of secondary progressive multiple sclerosis (SPMS), specifically in adult patients with active disease evidenced by relapses or imaging features of inflammatory activity.
The decision was supported by Phase 3 data drawn from 1,651 SPMS patients with varying degrees of disability, as quantified by a score of 3.0 to 6.5 on the Expanded Disability Status Scale.
